The post New Zealand’s CPI inflation rises to 3.1% YoY in Q4, vs 3.0% expected appeared on BitcoinEthereumNews.com. New Zealand’s Consumer Price Index (CPI) climbedThe post New Zealand’s CPI inflation rises to 3.1% YoY in Q4, vs 3.0% expected appeared on BitcoinEthereumNews.com. New Zealand’s Consumer Price Index (CPI) climbed

New Zealand’s CPI inflation rises to 3.1% YoY in Q4, vs 3.0% expected

New Zealand’s Consumer Price Index (CPI) climbed 3.1% YoY in the fourth quarter (Q4) of 2025, compared with the 3.0% increase seen in the third quarter, according to the latest data published by Statistics New Zealand on Friday. The market consensus was for a growth of 3.0% in the reported period

The quarterly CPI inflation eased to 0.6% in Q4 from the previous print of 0.1%, above the market consensus of 0.5%.

Market reaction

At the time of writing, the NZD/USD pair is trading 0.10% higher on the day to trade at 0.5908.

GDP FAQs

A country’s Gross Domestic Product (GDP) measures the rate of growth of its economy over a given period of time, usually a quarter. The most reliable figures are those that compare GDP to the previous quarter e.g Q2 of 2023 vs Q1 of 2023, or to the same period in the previous year, e.g Q2 of 2023 vs Q2 of 2022.
Annualized quarterly GDP figures extrapolate the growth rate of the quarter as if it were constant for the rest of the year. These can be misleading, however, if temporary shocks impact growth in one quarter but are unlikely to last all year – such as happened in the first quarter of 2020 at the outbreak of the covid pandemic, when growth plummeted.

A higher GDP result is generally positive for a nation’s currency as it reflects a growing economy, which is more likely to produce goods and services that can be exported, as well as attracting higher foreign investment. By the same token, when GDP falls it is usually negative for the currency.
When an economy grows people tend to spend more, which leads to inflation. The country’s central bank then has to put up interest rates to combat the inflation with the side effect of attracting more capital inflows from global investors, thus helping the local currency appreciate.

When an economy grows and GDP is rising, people tend to spend more which leads to inflation. The country’s central bank then has to put up interest rates to combat the inflation. Higher interest rates are negative for Gold because they increase the opportunity-cost of holding Gold versus placing the money in a cash deposit account. Therefore, a higher GDP growth rate is usually a bearish factor for Gold price.

Source: https://www.fxstreet.com/news/new-zealands-cpi-inflation-rises-to-31-yoy-in-q4-vs-30-expected-202601222214

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26